Literature DB >> 24630365

Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms.

Alexander Sidelmann Christensen1, Jonas Bech Møller2, Hans Carl Hasselbalch3.   

Abstract

BACKGROUND: The progression of kidney function and frequency of chronic kidney disease (CKD) in patients with the Philadelphia-negative myeloproliferative neoplasms (MPN) is unknown, although CKD is linked to increased mortality.
METHODS: This longitudinal retrospective study evaluates the estimated glomerular filtration rate (eGFR) in 143 MPN patients over a period of 9 years.
RESULTS: 29% of patients had CKD stage 3 or 4 at time of diagnosis. 20% of patients had a rapid annual loss of eGFR (>3mL/min/1.73m(2)) and eGFR was negatively correlated to monocyte and neutrophil counts.
CONCLUSION: Kidney impairment might contribute to the increased mortality observed in MPN patients.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chronic inflammation; Chronic kidney disease; Essential thrombocythemia; Hydroxyurea; Myelofibrosis; Myeloproliferative neoplasms; Polycythemia vera

Mesh:

Year:  2014        PMID: 24630365     DOI: 10.1016/j.leukres.2014.01.014

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  15 in total

1.  Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy.

Authors:  Yasutaka Fukuda; Marito Araki; Kouji Yamamoto; Soji Morishita; Tadaaki Inano; Kyohei Misawa; Tomonori Ochiai; Yoko Edahiro; Misa Imai; Hajime Yasuda; Akihiko Gotoh; Akimichi Ohsaka; Norio Komatsu
Journal:  Haematologica       Date:  2019-04-04       Impact factor: 9.941

2.  WITHDRAWN: Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era.

Authors:  Rachele Del Sordo; Rachele Brugnano; Carla Covarelli; Gioia Fiorucci; Franca Falzetti; Giorgio Barbatelli; Emidio Nunzi; Angelo Sidoni
Journal:  Clin Nephrol       Date:  2017-07-24       Impact factor: 0.975

3.  Beneficial effect of ACE inhibitors on kidney function in polycythemia vera.

Authors:  Ivan Krečak; Martina Morić Perić; Ivan Zekanović; Hrvoje Holik; Božena Coha; Velka Gverić-Krečak; Marko Lucijanić
Journal:  Wien Klin Wochenschr       Date:  2021-02-08       Impact factor: 1.704

4.  Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms.

Authors:  Marie Bak; Torben Lykke Sørensen; Esben Meulengracht Flachs; Ann-Dorthe Zwisler; Knud Juel; Henrik Frederiksen; Hans Carl Hasselbalch
Journal:  JAMA Ophthalmol       Date:  2017-08-01       Impact factor: 7.389

5.  Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis.

Authors:  Marko Lucijanic; Davor Galusic; Ivan Krecak; Martina Sedinic; Hrvoje Holik; Vlatka Perisa; Martina Moric Peric; Ivan Zekanovic; Tajana Stoos-Veic; Rajko Kusec
Journal:  Ann Hematol       Date:  2020-08-29       Impact factor: 3.673

6.  Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment.

Authors:  Ken Ogasawara; William B Smith; Christine Xu; Jian Yin; Maria Palmisano; Gopal Krishna
Journal:  Cancer Chemother Pharmacol       Date:  2020-05-24       Impact factor: 3.333

7.  Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era.

Authors:  Rachele Del Sordo; Rachele Brugnano; Carla Covarelli; Gioia Fiorucci; Franca Falzetti; Giorgio Barbatelli; Emidio Nunzi; Angelo Sidoni
Journal:  Clin Nephrol Case Stud       Date:  2017-07-24

8.  Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib.

Authors:  Arun Rajasekaran; Thuy-Trang Ngo; Maen Abdelrahim; William Glass; Amber Podoll; Srdan Verstovsek; Ala Abudayyeh
Journal:  BMC Nephrol       Date:  2015-08-01       Impact factor: 2.388

9.  Renal Function and All-Cause Mortality Risk Among Cancer Patients.

Authors:  Yan Yang; Hui-Yan Li; Qian Zhou; Zhen-Wei Peng; Xin An; Wei Li; Li-Ping Xiong; Xue-Qing Yu; Wen-Qi Jiang; Hai-Ping Mao
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

Review 10.  MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives.

Authors:  Hans Carl Hasselbalch; Mads Emil Bjørn
Journal:  Mediators Inflamm       Date:  2015-10-28       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.